1. A potent, broadly neutralizing human monoclonal antibody that efficiently protects hACE2-transgenic mice from infection with the Wuhan, BA.5, and XBB.1.5 SARS-CoV-2 variants.
- Author
-
Guselnikov SV, Baranov KO, Kulemzin SV, Belovezhets TN, Chikaev AN, Murasheva SV, Volkova OY, Mechetina LV, Najakshin AM, Chikaev NA, Solodkov PP, Sergeeva MV, Smirnov AV, Serova IA, Serov OL, Markhaev AG, Kononova YV, Alekseev AY, Gulyaeva MA, Danilenko DM, Battulin NR, Shestopalov AM, and Taranin AV
- Subjects
- Animals, Humans, Mice, Spike Glycoprotein, Coronavirus immunology, Spike Glycoprotein, Coronavirus genetics, Pandemics prevention & control, Betacoronavirus immunology, Betacoronavirus genetics, Broadly Neutralizing Antibodies immunology, Disease Models, Animal, Pneumonia, Viral immunology, Pneumonia, Viral virology, Pneumonia, Viral prevention & control, Coronavirus Infections immunology, Coronavirus Infections virology, Coronavirus Infections prevention & control, SARS-CoV-2 immunology, COVID-19 immunology, COVID-19 prevention & control, COVID-19 virology, Mice, Transgenic, Angiotensin-Converting Enzyme 2 immunology, Angiotensin-Converting Enzyme 2 genetics, Angiotensin-Converting Enzyme 2 metabolism, Antibodies, Viral immunology, Antibodies, Monoclonal immunology, Antibodies, Neutralizing immunology
- Abstract
The COVID-19 pandemic has uncovered the high genetic variability of the SARS-CoV-2 virus and its ability to evade the immune responses that were induced by earlier viral variants. Only a few monoclonal antibodies that have been reported to date are capable of neutralizing a broad spectrum of SARS-CoV-2 variants. Here, we report the isolation of a new broadly neutralizing human monoclonal antibody, iC1. The antibody was identified through sorting the SARS-CoV-1 RBD-stained individual B cells that were isolated from the blood of a vaccinated donor following a breakthrough infection. In vitro , iC1 potently neutralizes pseudoviruses expressing a wide range of SARS-CoV-2 Spike variants, including those of the XBB sublineage. In an hACE2-transgenic mouse model, iC1 provided effective protection against the Wuhan strain of the virus as well as the BA.5 and XBB.1.5 variants. Therefore, iC1 can be considered as a potential component of the broadly neutralizing antibody cocktails resisting the SARS-CoV-2 mutation escape., Competing Interests: Patent applications are being filed for the iC1 antibody. KB, LM, OV, AN, NC, and AT are employees of IMGEN+, LLC. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The authors declare that this study received funding from IMGEN+ LLC. The funder had the following involvement in the study: collection of data., (Copyright © 2024 Guselnikov, Baranov, Kulemzin, Belovezhets, Chikaev, Murasheva, Volkova, Mechetina, Najakshin, Chikaev, Solodkov, Sergeeva, Smirnov, Serova, Serov, Markhaev, Kononova, Alekseev, Gulyaeva, Danilenko, Battulin, Shestopalov and Taranin.)
- Published
- 2024
- Full Text
- View/download PDF